NCT01611480View on ClinicalTrials.gov

Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Primary Completion Date

January 31, 2013

Conditions
Actinic Keratosis
Interventions
DRUG

Imiquimod (topical use)

Trial Locations (1)

Unknown

5 Locations, Germany

Sponsors

Lead Sponsor

Moberg Pharma AB
All Listed Sponsors
lead

Moberg Pharma AB

INDUSTRY

NCT01611480 - Efficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During 2 x 2 Weeks Treatment for Actinic Keratosis on the Head | Biotech Hunter | Biotech Hunter